Alendronate/calcitriol - Yuyu PharmaAlternative Names: Maxmarvil
Latest Information Update: 06 Jan 2016
At a glance
- Originator Yuyu
- Class Antihyperglycaemics; Bisphosphonates; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Vitamin D analogues
- Mechanism of Action Osteoclast inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
Most Recent Events
- 01 Jan 2012 Launched for Osteoporosis in Thailand (PO)
- 01 Jan 2004 Launched for Osteoporosis in South Korea (PO)